ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 2591

Lupus-Related Reproductive Health Experiences and Needs of Women of Childbearing Age: A Qualitative Study
Abstract Number: 2592

The Effects of Early Life Trauma and Socioeconomic Position on Systemic Lupus Erythematosus Risk in Adulthood
Abstract Number: 2593

A Long-term Synovial Tissue 3D Model Incorporating Fibroblasts, Macrophages, Endothelial Cells, and Other Immune Cells Such as Innate Lymphoid Cells Enables Animal Model-Independent Rheumatoid Arthritis Research
Abstract Number: 2594

A Novel Therapeutically Active CSF-1R Agonist Promotes Tissue Macrophages Inflammation Resolution and Induces Tissue Repair Pathways
Abstract Number: 2595

TGF-β Activated Kinase 1 (TAK1) Inhibition Suppresses Synovial Inflammation and Tissue Destruction Mediated by Activated Juvenile Idiopathic Arthritis Synovial Fibroblasts
Abstract Number: 2596

Clock Gene Bmal1 Contributes to Inflammation via Phosphorylation of NF-κB/p65 in RA-FLS
Abstract Number: 2597

The Stromal-cell Derived Cytokine interleukin-17D Attenuates Joint Inflammation
Abstract Number: 2598

p300 KAT Inhibition Selectively Targets Multiple Cell Types Involved in Chronic Inflammation and Downregulates Key Inflammatory Cytokines
Abstract Number: 2599

Xist Deletion in B Cells Results in Systemic Lupus Erythematosus Phenotypes
Abstract Number: 2600

Repression of the Aryl-hydrocarbon Receptor Prevents Oxidative Stress and Ferroptosis of Intestinal γδT Cells and Alleviates Systemic Lupus Erythematosus
Abstract Number: 2601

Platelets Specifically Interact with Remigrating Neutrophils and Promote Immunogenic Cellular Death in Systemic Lupus
Abstract Number: 2602

Genetics of Sex Dimorphism in Clinical Manifestations of Systemic Lupus Erythematosus
Abstract Number: 2603

A Human Lupus Gut Pathobiont Accelerates Systemic Inflammation, Autoantibody Production and T Cell Dysregulation
Abstract Number: 2604

Altered Expression of Ecto-5′-Nucleotidase (NT5E) in SLE Patients Based on Disease-associated Genotype
Abstract Number: 2605

Clarifying Misbeliefs & Resolving Decisional Conflicts About Hydroxychloroquine (HCQ) Through a Shared Decision-Making Tool (HCQ-SAFE©)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].